Expert Insight - Global Axial Spondyloarthritis Market
BIS Healthcare Analysts in conversation with: Khalid Shirazy Rheumatologist MD. MSc
BIS Research provides premium market intelligence on deep technologies that have the potential to cause a high level of disruption in the market in the next few years. We excel in conducting market viability analysis for technologies that are still in the nascent stages of their lifecycle.
For each topic that we cover, BIS Research’s analysts interact with dozens of industry experts to scan, analyze, and predict the future of the concerned technology and its market. Our ‘Expert Insight’ series is one such initiative, where we make the industry insights available to senior executives in a short and quick to read format.
The growing interest of the pharmaceutical industry in the therapeutic potential for treating axial spondyloarthritis has been a catalyst for the progress in the global axial spondyloarthritis market. The recent increase in the number of drug approvals received for treating different types of axial spondyloarthritis is considered to have added value to the emerging potential drug development. The global axial spondyloarthritis market is expected to witness high growth, attributed to the growing prevalence of axial spondyloarthritis, favorable regulatory environment, and increase in adoption of biological agents in the field of axial spondyloarthritis.
BIS Healthcare Analysts in conversation with: Khalid Shirazy Rheumatologist MD. MSc
BIS Research provides premium market intelligence on deep technologies that have the potential to cause a high level of disruption in the market in the next few years. We excel in conducting market viability analysis for technologies that are still in the nascent stages of their lifecycle.
For each topic that we cover, BIS Research’s analysts interact with dozens of industry experts to scan, analyze, and predict the future of the concerned technology and its market. Our ‘Expert Insight’ series is one such initiative, where we make the industry insights available to senior executives in a short and quick to read format.
The growing interest of the pharmaceutical industry in the therapeutic potential for treating axial spondyloarthritis has been a catalyst for the progress in the global axial spondyloarthritis market. The recent increase in the number of drug approvals received for treating different types of axial spondyloarthritis is considered to have added value to the emerging potential drug development. The global axial spondyloarthritis market is expected to witness high growth, attributed to the growing prevalence of axial spondyloarthritis, favorable regulatory environment, and increase in adoption of biological agents in the field of axial spondyloarthritis.